C.H. Boehringer Sohn AG & Ko. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's 20 largest pharmaceutical companies.[circular reference] Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.
|Founded||Ingelheim am Rhein, Germany (1885 )|
|Products||Pharmaceuticals and Animal Health|
|Revenue||€15.9 billion (2017)|
|€2.9 billion (2016)|
|Total assets||€20.05 billion (2014)|
|Total equity||€8.111 billion (2014)|
|Owner||Boehringer, Liebrecht and von Baumbach families|
Number of employees
Boehringer Ingelheim works in human pharmaceuticals, animal health, and biopharmaceuticals. The group consists of 145 affiliated companies with around 50,000 employees in 2017 in all continents. Research and development facilities were in five sites and 20 production plants in 13 countries. The research and development facilities are located in Biberach (Germany), Ridgefield (Connecticut), Vienna, Kobe, and Milan (closed in 2017). Over 8,000 employees work for Boehringer Ingelheim in research and development.
- 1885: Albert Boehringer buys a small tartar factory in Ingelheim am Rhein; work begins on 1 August.
- 1886: The factory commences production of tartaric acid for use in the food industry (e.g. in baking powder and carbonated beverages).
- 1893: Albert Boehringer renames the company C. H. Boehringer Sohn (CHBS) after his father, Christoph Heinrich Boehringer.
- 1893: While experimenting with the production of citric acid, lactic acid is formed. Albert Boehringer develops this process, with the intention of producing lactic acid on a larger scale.
- 1895: Lactic acid is produced on an industrial scale, and is successful commercially.
- 1917: Professor Heinrich Otto Wieland, chemist, future Nobel Prize winner and cousin of Albert Boehringer, sets up the company’s research department.
- 1928: Albert Boehringer purchases Dr. Karl Thomae, a company based in Winnenden near Stuttgart.
- 1946: Dr. Karl Thomae GmbH is re-opened in Biberach an der Riss with a staff of 70 people.
- 1954: The company hires former Nazi Fritz Fischer after he is released from jail. Fischer was convicted of war crimes and crimes against humanity at the Nuremberg Trials. This has never been corroborated or authenticated.
- 1955: The Animal Health division is established as the company acquires Pfizer’s veterinary programme.
- 1966: A subsidiary company named Boehringer Ingelheim Hellas was founded and the company started buisiness in Greece. A new factory was built close to Athens at Koropi
- 1971: The foreign subsidiary, Boehringer Ingelheim Pharmaceuticals, Inc is founded in Ridgefield, Connecticut (USA). This site is soon expanded, and becomes the company’s North American research centre.
- 1985: The Research Institute of Molecular Pathology (IMP) is established in Vienna through a collaboration with Genentech; it opens in 1988.
- 1986: The biotechnological centre in Biberach begins production of biopharmaceuticals from cell cultures.
- 1998: The merging of Boehringer Ingelheim KG and Dr. Karl Thomae GmbH founds Boehringer Ingelheim Pharma KG.
In 2010 BI, through its Boehringer Ingelheim Japan Investment GK subsidiary, acquired all outstanding shares of SSP CO., Ltd, with Nippon Boehringer Ingelheim Co., Ltd already holding 60.2% of SSP CO's shares.
In May 2015, the company acquired the investigational drug PXS4728A from Pharmaxis’. In July, the company sold its Roxane business to Hikma Pharmaceuticals Plc for $2.65 billion ($1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $125 million based on performance milestones. On the same day the company announced it would partner with Hanmi Pharmaceutical to develop and commercialise HM61713, a third generation treatment for EGFR mutation-positive lung cancer. Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new BACE program for Alzheimer's.
In July 2016 the company sold the commercialisation rights to BI 655066 (Risankizumab), to AbbVie for $595 million upfront as well as undisclosed milestone payments and royalties. BI 655066 is a drug in late-stage testing for psoriasis, and in earlier testing for Crohn's disease, psoriatic arthritis and asthma. In September of the same year the company announced it would acquire ViraTherapeutics for €210 million ($230 million), a developer of oncolytic virus therapies, dependant on the success of Phase I trials.
In April 2018 the company announced that it would launch an immuno-oncology partnership with OSE Immunotherapeutics worth up-to-$1.4 billion, focussing on developing OSE's late-preclinical-stage candidate OSE-172, a checkpoint inhibitor antibody designed to treat solid tumors. In the same month Boehringer announced a partnership with Topas Therapeutics and their virus-based vectors. In mid-September the company exercised its option to acquire viral cancer therapy developer, ViraTherapeutics, for €210 million ($245 million).
In March 2019 Boehringer announced it would acquire ICD Therapeutics.
2016 – Sanofi asset swapEdit
In June 2016, the company announced it had struck an asset-swap deal with Sanofi, Boehringer would sell its consumer health division (valuing it at €6.7 billion) and €4.7 billion in cash, whilst acquiring the Merial animal health division (valuing it at €11.4 billion / $12.4 billion). The deal could mean that Boehringer is now one of the animal healthcare global leaders. In September of the same year, Amgen announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma. As part of the asset swap, Boehringer and Merial sold a number of assets to Ceva Santé Animale - namely some animal health vaccines and pharmaceuticals from the Merial portfolio for swine, bovine and companion animals, as well as some intellectual property, manufacturing processes and R&D activities. In October 2016 the company sold its US pet vaccines business and a manufacturing plant for $885 million, to Eli Lilly Cos Elanco Animal Health division.
Boehringer Ingelheim is involved in publicly funded collaborative research projects with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.
Boehringer Ingelheim is a globally operating company, with 146 subsidiaries around the globe. The company's largest site and corporate headquarters is in Ingelheim am Rhein near Mainz and Frankfurt, Germany. Their main business regions are Europe, North America and Asia. The Research Institute of Molecular Pathology in Vienna (Austria), founded in 1985, has had Boehringer Ingelheim as its main sponsor since 1993.
Closure of drug manufacturing plantEdit
In 2011 Ben Venue Laboratories in Bedford, Ohio, a division of Boehringer Ingelheim, voluntarily shut down after a U.S. Food and Drug Administration inspectors' report that found the plant had rusty tools, mold, and a barrel of 'unknown liquid', later found to be urine. The company invested US$300,000,000 to upgrade the drug manufacturing plant, and limited production resumed in October 2012. However, on 3 October 2013, Ben Venue announced that it would be ceasing production by the end of 2013 due to being unable to "return to sustainable production."
Key product linesEdit
- Actilyse (alteplase)
- Aggrenox (dipyridamole / acetylsalicylic acid)
- Alna / Flomax (tamsulosin)
- Aptivus (tipranavir)
- Berodual (ipratropium bromide / fenoterol)
- Combivent (ipratropium bromide / salbutamol)
- Gilotrif / Giotrif (afatinib)
- Jardiance (empagliflozin)
- Jentadueto / TrajentaDuo (linagliptin / metformin)
- Metalyse (tenecteplase)
- Micardis (telmisartan)
- Micardis Plus / Micardis HCT (telmisartan / hydrochlorothiazide)
- Mirapex / Sifrol (pramipexole)
- Ofev / Vargatef (Nintedanib)
- Mobic / Movalis (meloxicam)
- Pradaxa (dabigatran etexilate)
- Spiriva (tiotropium bromide)
- Trajenta / Tradjenta (linagliptin)
- Twynsta (telmisartan / amlodipine)
- Viramune (nevirapine)
Consumer Health Care:
- Antistax (red vine leaf extract)
- Bisolvon (bromhexine)
- Buscopan / Buscapina (hyoscine butylbromide)
- Dulcolax (bisacodyl)
- Zantac (ranitidine)—75 and 150 mg tablets; 300 mg tablets, syrup and solution for injection are manufactured by GlaxoSmithKline
- Mucoangin / Mucosolvan (ambroxol)
- Pharmaton (standardized ginseng extract, vitamins, minerals, trace elements)
- Thomapyrin (acetylsalicylic acid, paracetamol, caffeine)
|Drug Name||Description||Potential Indication||Testing Phase|
|Olodaterol||Long-acting beta-agonist||Chronic obstructive pulmonary disease (COPD)||Approved|
|Tiotropium||Long acting muscarinic antagonist||Cystic fibrosis (CF) / asthma. Already approved for chronic obstructive pulmonary disease (COPD)||Approved|
|Nintedanib||Triple angiokinase inhibitor, simultaneously blocks VEGFR, FGFR, PDGFR||Idiopathic pulmonary fibrosis (IPF) / non-small cell lung cancer (NSCLC) / ovarian cancer||Phase III|
|Afatinib||Irreversible ErbB family blocker||Breast cancer / head and neck cancer. Already approved for non-small cell lung cancer (NSCLC)||Phase III|
|Volasertib||PLK1 antagonist||Various cancer types||Phase III|
|Deleobuvir (formerly BI 207127)||NS5B RNA-dependent polymerase inhibitor||Hepatitis C||Phase III|
|Faldaprevir (formerly BI 201335)||NS3/4A protease inhibitor||Hepatitis C||Phase III|
|Empagliflozin||SGLT-2-inhibitor||Diabetes mellitus type II||Approved|
|Idarucizumab||Humanized antibody fragment (FAB), specific reversal agent to dabigatran||Reversal of dabigatran-induced anticoagulation in case of an emergency||Phase III|
In October 2012 Boehringer Ingelheim settled a "qui tam" (whistleblower) case with the U.S. government for $95 million alleging "off-label" marketing of the drugs Aggrenox, Atrovent, Combivent, and Micardis for uses that weren't approved by the US Food and Drug Administration and were not covered by federal health care programs.
In August 2012, Pradaxa claims filed in the federal court were consolidated in a multi-district litigation in the Southern District of Illinois before Chief Judge David R. Herndon. On 28 May 2014, a $650 million settlement was announced on behalf of approximately 3,900 claimants who were injured by the drug Pradaxa made by Boehringer Ingelheim Pharmaceuticals, Inc. The drug is alleged to cause severe bleeding events and/or hemorrhaging to those who were taking the drug.
In popular cultureEdit
The Company is mentioned as being a former place of work for one of the Characters in Season Two, Episode Ten, of the Scandinavian Police thriller Series, The Bridge (Danish/Swedish TV series).
- Editorial, Reuters. "Boehringer eyes marked sales gain, boosted by animal health".
- List of largest pharmaceutical companies by revenue#Top pharmaceutical companies with revenue greater than $10 billion
- Kroll, Kerry A. Dolan and Luisa. "Billionaire Dynasties" Check
|url=value (help). Forbes. Retrieved 2019-04-03.
- "Boehringer Ingelheim Logo". Famous Logos. Retrieved 18 August 2011.
- "1948-1988". mena.boehringer-ingelheim.com. Retrieved 2018-02-22.
- "Boehringer Ingelheim to acquire STEAG microParts GmbH". www.analytica-world.com.
- "Boehringer Ingelheim Announces Acquisition of the Remaining Shares in Boehringer Ingelheim Shionogi Vetmedica (BISV)".
- "Actimis.com" (PDF). www.actimis.com. Retrieved 17 February 2019.
- "Boehringer Ingelheim to Acquire Some Fort Dodge Equine Products – The Horse". thehorse.com. 3 November 2009. Retrieved 7 November 2018.
- "Boehringer Ingelheim announces its intention to acquire all the outstanding shares in SSP Co., Ltd. ("SSP") through a tender offer". 18 February 2010.
- site., Who made this. "Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional's FX125L - Cambridge Enterprise".
- "Boehringer Ingelheim acquires Pharmaxis' PXS4728A". www.europeanpharmaceuticalreview.com.
- Fourcade, Marthe (28 July 2015). "Hikma to Buy Boehringer Ingelheim's Roxane for $2.65 Billion". Bloomberg.
- "Hikma Buys Roxane for $2.65B, Expanding U.S. Generics Presence - GEN News Highlights - GEN".
- "Boehringer Licenses Hanmi Lung Cancer Drug for Up-to $730M+ - GEN News Highlights - GEN".
- "Boehringer dumps its Alzheimer's BACE pact with Vitae - FierceBiotech".
- "Portfolio - Trek Therapeutics".
- Daily, Investor's Business. "AbbVie Bolsters Immunology Business, Acquires Boehringer Drug - Stock News & Stock Market Analysis - IBD". www.investors.com.
- "Boehringer Ingelheim Bets 230 Million on Newcomer ViraTherapeuticss Immune Oncology Pipeline". www.biospace.com.
- "Boehringer offers €210M to get into Virus-based Immuno-Oncology". 29 September 2016.
- "Boehringer nabs up to €210M oncolytic virus option deal with Austrian startup - FierceBiotech". www.fiercebiotech.com.
- "Boehringer Ingelheim, Topas Launch Antigen-Specific Tolerance Induction Partnership". genengnews.com. 24 April 2018. Retrieved 7 November 2018.
- "Boehringer Ingelheim to Co-Develop ViraTherapeutics' Oncolytic Virus Platform, Candidate". genengnews.com. 28 September 2016. Retrieved 7 November 2018.
- "Aiming for top dog status, Sanofi and Boehringer swap animal and consumer health units - FiercePharma".
- "Amgen Buys Rights to Myeloma BiTE Immunotherapy from Boehringer Ingelheim - GEN News Highlights - GEN".
- "Boehringer Ingelheim announces agreement with Ceva Santé Animale for the sale of certain Merial assets". boehringer-ingelheim.com.
- "FTC Requires Divestitures as Condition to Proposed $13.53 Billion Deal between German Pharmaceutical Boehringer Ingelheim and Paris-based Sanofi". 28 December 2016.
- "domain-b.com : Eli Lilly to buy Boehringer Ingelheim's US pet vaccines business for $885 mn". www.domain-b.com.
- "Elanco Animal Health Enters Agreement to Acquire Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio".
- Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN 978-1-58829-638-2. PMID 18449490.
- "InnoMed PredTox". Genedata. InnoMed PredTox Members. Archived from the original on 4 December 2012. Retrieved 28 November 2014.
- Innovative Medicines Initiative. "IMI Call Topics 2008" (PDF). EUROSFAIRE. France: Ministry of Higher Education and Research. Retrieved 2008-08-25.
- Staff (15 January 2015). "Boehringer May Sell U.S. Generics Unit". Pharmaceutical Manufacturing. Putman Media. Bloomberg.
- "Ben Venue Laboratories – Voluntary Shutdown". Drug Safety and Availability. USFDA. 30 November 2011. Retrieved 18 October 2012.
- Thomas, Katie (18 October 2012). "Lapses at Big Drug Factories Add to Shortages and Danger". The New York Times. p. A1.
- "Ben Venue Laboratories, Inc to Cease Production" (Press release). Ben Venu Laboratories. 3 October 2013. Archived from the original on 4 October 2013.
- "Pipeline". Boehringer Ingelheim. Retrieved 12 September 2013.
- "Press Announcements - FDA approves Jardiance to treat type 2 diabetes".
- "Boehringer Ingelheim pays $95 million to settle whistleblower case" (Press release). Phillips & Cohen. 25 October 2012.
- Thomas, Katie (28 May 2014). "$650 Million to Settle Blood Thinner Lawsuits". The New York Times.